GENFIT Updates 2024 Outlook Following Acceptance of Elafibra

US Food and Drug Administration has granted Priority Review for New Drug Application for elafibranor in PBC, and European Medicine Agency has also validated the Marketing Authorization Application ...

Related Keywords

Switzerland , Cambridge , Cambridgeshire , United Kingdom , Massachusetts , United States , Paris , France General , France , Stephanie Boyer , Pascal Prigent , Nasdaq , Drug Administration , Uncertainties Of The Company , Exchange Commission , Euronext , European Medicine Agency , Priority Review , New Drug Application , Marketing Authorization Application , Acute On Chronic Liver Failure , Liver Meeting , New England Journal , Capital Market Day , Primary Sclerosing Cholangitis , Urea Cycle Disorders , Organic Acidemias , Breakthrough Therapy Designation , Chronic Liver Failure , Nasdaq Global Select Market , Private Securities Litigation Reform Act , Registration Document , Half Year Business , Financial Report , Drug User Fee , Markets ,